The Cochlear (ASX: COH) share price is up 4% this last week

It's been a good recovery week for shares in the hearing device manufacturer.

| More on:
Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Limited (ASX: COH) share price is having a great start to the new month after struggling through a less than ideal August.

Cochlear shares fell 4.97% over the course of last month, with the biggest catalyst for the drop being the company's financial year 2021 earnings.

Fortunately, Cochlear's stock ended August and started September on an upward trajectory. It has gained 4.47% over the course of this week.

Right now, the Cochlear share price is trading at $237.10, gaining 1.96% today alone.

Let's take a look at what's been happening lately.

What's up with Cochlear this week?

Shares in the hearing device manufacturer appear to be recovering after a poor month's performance in August.

It has pulled itself up by the bootstraps this week after posting lower than expected profits for the 2021 financial year and less than satisfactory guidance for the financial year 2022.

As The Motley Fool Australia reported at the time, despite the company reporting profits inside its previously given guidance, it fell short of the market's expectations.

The Cochlear share price suffered as a result, falling 7.4% on the day it posted its earnings results. The following week, shares in the company continued their downwards trajectory, falling another 4.3%.

The market hasn't heard any fresh news from Cochlear since. However, investor confidence in the ASX healthcare giant appears to have rebounded and its shares are recovering the lost ground.

Cochlear share price snapshot

The Cochlear share price has performed well on the ASX this year.

Including this week's upturn, it has gained 24% since the start of 2021 and is 20% higher than it was this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

The pros and cons of buying CSL shares right now

It’s an interesting time to consider this healthcare giant.

Read more »

Vanadium Resources share price person riding rocket indicating share price increase
Healthcare Shares

Why did this ASX biotech stock explode 52% higher on Monday?

Shareholders of this stock were smiling today. What happened?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is everyone talking about ResMed shares?

It’s been a good year for ResMed shareholders. Let’s find out why.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »